

1623



In re Application of:

Indra Prakash

Application No.: 09/859,439

Filed: May 18, 2001

For: SYNTHESIS OF N-[N-(3,3-DIMETHYLBUTYL)
-L- α -ASPARTYL]-L-PHENYLALANINE
1-METHYL ESTER USING OXAZOLIDINONE
DERIVATIVES

Docket No. 02047.000154

Examiner: Paul A. Zucker

Group Art Unit: 1623

Date: March 18, 2002

RECEIVED
APR 03 2002
TECH CENTER 1600/2900

THE COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

☒ No additional fee is required.

The fee has been calculated as shown below

CLAIMS AS AMENDED						
	(2) CLAIMS REMAINING AFTER AMENDMENT		(4) HIGHEST NO. PREVIOUSLY PAID FOR	(5) PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL CLAIMS	* 20	MINUS	** 20	= 0	x \$9 \$18	0
INDEP. CLAIMS	* 1	MINUS	*** 1	= 0	x \$42 \$84	0
Fee for Multiple Dependent claims \$140°/\$280						
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT---						0

- * If the entry in Column 2 is less than the entry in Column 4, write "0" in Column 5.
- ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

☐ °Verified Statement claiming small entity status is enclosed, if not filed previously.

☐ A check in the amount of \$ _____ is enclosed.

☐ Charge \$ _____ to Deposit Account No. 06-1205. A duplicate copy of this sheet is enclosed.


☒ Any prior general authorization to charge an issue fee under 37 C.F.R. 1.18 to Deposit Account No. 06-1205 is hereby revoked. The Commissioner is hereby authorized to charge any additional fees under 37 C.F.R. 1.16 and 1.17 which may be required during the entire pendency of this application, or to credit any overpayment, to Deposit Account No. 06-1205. A duplicate copy of this paper is enclosed.

☐ A check in the amount of \$ _____ to cover the fee for a _____ month extension is enclosed.

☐ A check in the amount of \$ _____ to cover the Information Disclosure Statement fee is enclosed.

☒ Applicant's undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Raymond R. Mandra
Attorney for Applicant
Registration No. 34,382

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3801
Facsimile: (212) 218-2200

Form #120

NY_MAIN 246248 v 1

02047.000134



PATENT APPLICATION

#6/A
4402
[Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 03 2002

TECH CENTER 1600/2900

In re Application of:

INTARA PRAKASH

Application No.: 09/351,439

Filed: May 18, 2001

For: SYNTHESIS OF N-[N-(3,
3-DIMETHYLBUTYL)-L-
 α -ASPARTYL]-L-
PHENYLALANINE 1-
METHYL ESTER USING
OXAZOLIDINONE
DERIVATIVES

Examiner: P. Zucker

Group Art Unit: 1623

March 18, 2002

Commissioner for Patents
Washington D.C. 20231

AMENDMENT

Sir:

In response to the Office Action dated December 17, 2001, Applicant respectfully requests reconsideration in view of the following amendments and remarks in support of patentability. It is believed that no fees are due; however, if any fees are due, please charge them to Deposit Account No. 06-1205.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

March 18, 2002
(Date of Deposit)

Raymond R. Mandra (Reg. No. 34,382)
(Name of Attorney for Applicant)

[Signature]
Signature

March 18, 2002
Date of Signature